We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

HSTO Histogen Inc

0.00 (0.0%)
Nov 30 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 0.6551
Ask Price 0.675
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Histogen Inc HSTO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.658 19:00:00
Open Price Low Price High Price Close Price Prev Close
0.658 0.658
Trades Volume Avg Volume 52 Week Range
0 0 - 0.3596 - 1.6201
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.658 USD

Histogen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.81M - - - -26.45
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Histogen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No HSTO Message Board. Create One! See More Posts on HSTO Message Board See More Message Board Posts

Historical HSTO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.690.8150.35960.5325116721,380-0.032-4.64%
6 Months0.830.990.35960.5798025199,186-0.172-20.72%
1 Year1.011.62010.35961.14395,856-0.352-34.85%
3 Years31.0039.600.359614.611,195,178-30.34-97.88%
5 Years88.20100.000.359614.991,021,370-87.54-99.25%

Histogen Description

Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |